Title : Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).

Pub. Date : 2013 Dec

PMID : 24005613






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Vandetanib is an oral once daily administered inhibitor of VEGFR-, EGFR- and RET-signaling with activity in combination with chemotherapy in some solid tumours. vandetanib kinase insert domain receptor Homo sapiens